0001415889-22-011708.txt : 20221122
0001415889-22-011708.hdr.sgml : 20221122
20221122200011
ACCESSION NUMBER: 0001415889-22-011708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221118
FILED AS OF DATE: 20221122
DATE AS OF CHANGE: 20221122
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Eldridge George A
CENTRAL INDEX KEY: 0001413006
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40544
FILM NUMBER: 221411989
MAIL ADDRESS:
STREET 1: C/O TARGANTA THERAPEUTICS CORPORATION
STREET 2: 222 THIRD STREET SUITE 2300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aerovate Therapeutics, Inc.
CENTRAL INDEX KEY: 0001798749
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831377888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-443-2400
MAIL ADDRESS:
STREET 1: 930 WINTER STREET
STREET 2: SUITE M-500
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4-11222022_081101.xml
X0306
4
2022-11-18
0001798749
Aerovate Therapeutics, Inc.
AVTE
0001413006
Eldridge George A
C/O AEROVATE THERAPEUTICS, INC.
930 WINTER STREET, SUITE M-500
WALTHAM
MA
02451
false
true
false
false
SEE REMARKS
Common Stock
2022-11-18
4
M
0
861
2.14
A
2821
D
Common Stock
2022-11-18
4
S
0
780
19.4541
D
2041
D
Common Stock
2022-11-18
4
S
0
81
20.1335
D
1960
D
Common Stock
2022-11-21
4
M
0
2
2.14
A
1962
D
Common Stock
2022-11-21
4
S
0
2
19
D
1960
D
Common Stock
2022-11-22
4
M
0
174
2.14
A
2134
D
Common Stock
2022-11-22
4
S
0
174
19.0121
D
1960
D
Stock Option (Right to Buy)
2.14
2022-11-18
4
M
0
861
0
D
2031-04-01
Common Stock
861
97815
D
Stock Option (Right to Buy)
2.14
2022-11-21
4
M
0
2
0
D
2031-04-01
Common Stock
2
97813
D
Stock Option (Right to Buy)
2.14
2022-11-22
4
M
0
174
0
D
2031-04-01
Common Stock
174
97639
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 15, 2022.
Includes 1,960 shares purchased under the Issuer's 2021 Employee Stock Purchase Plan on October 31, 2022 in a transaction that is exempt under Rule 16b-3(c) and 16b-3(d).
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.06 to $20.045, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.095 to $20.29, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.03, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
A total of 98,676 shares subject to an employee stock option were granted on April 1, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Officer Title: Chief Financial Officer and Treasurer
/s/ George A. Eldridge
2022-11-22